Labyrinth BioPharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $5M

Overview

Labyrinth BioPharma is a specialized CDMO focused on lyophilization and formulation development, serving the oncology and diagnostics sectors. Founded in 2019 and based in Bloomington, Indiana, it leverages deep scientific expertise to offer end-to-end development and manufacturing services for complex drug products. As a private, service-oriented company, it generates revenue by providing technical consulting, process development, and GLP manufacturing to biopharma clients.

Oncology

Technology Platform

Specialized expertise in formulation science and lyophilization (freeze-drying) cycle development for stabilizing complex drug products, including small molecules, biologics, suspensions, emulsions, and diagnostics.

Funding History

1

Total raised:$5M

Seed$5MUndisclosedJun 15, 2021

Opportunities

Growing demand for lyophilization expertise driven by the increasing complexity of biologic and oncology drugs, which often require stabilization.

The trend towards outsourcing by virtual and small biotech companies creates a steady client pipeline for niche technical service providers.

Risk Factors

Revenue is project-dependent and susceptible to biotech funding cycles.

Faces competition from both large, full-service CDMOs and other niche consultants.

Reputation relies entirely on successful technical execution for clients.

Competitive Landscape

Competes with large, full-service CDMOs (e.g., Catalent, Lonza) that have lyophilization capabilities and with smaller, specialized consulting firms. Differentiation is based on deep, hands-on scientific expertise and a focus on client collaboration rather than scale.

More companies in Drug Delivery & Formulation →More companies in United States →